4-chlorophenyl phosphate | 13388-88-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磷酸及其衍生物
• 英文名称: 4-chlorophenyl phosphate
• 英文别名: p-chlorophenyl phosphate；p-Chlorphenylphosphat；4-Chlorphenyl-phosphat；<4-Chlorphenyl>-phosphat；Phosphorsaeure-mono-p-chlorphenylester；(4-Chlorophenyl) dihydrogen phosphate
• CAS: 13388-88-0
• 化学式: C₆H₆ClO₄P
• 分子量: 208.538
• InChiKey: BBAMTDMNXVSCRU-UHFFFAOYSA-N

物化性质

• 熔点：
  93 °C
• 沸点：
  381.7±44.0 °C(Predicted)
• 密度：
  1.628±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-chlorophenyl phosphate 在 氯甲基甲基醚 作用下， 以 乙腈 为溶剂， 生成 symm. Bis-(p-chlor-phenyl-ester) d. Phosphorsaeure; P(1).P(2)-4-Dichlor-phenyl-pyrophosphat
  参考文献：
  名称：

  在高反应性卤化物存在下，腈促进磷酰基转移

  摘要：

  腈类，例如乙腈和苄腈慢慢在升高的温度下与反应单取代磷酸，得到符号-pyrophosphates。预先添加高反应性的卤化物，例如氯甲基醚或硫醚，产生了更有效的磷酰基转移。酸酐和酯都可以这种方式产生。

  DOI：

  10.1039/j39690000074
• 作为产物：
  描述：

  4-氯苯基二氯磷酸酯 生成 4-chlorophenyl phosphate
  参考文献：
  名称：

  合成双脱氧核糖核苷酸嵌段的简化策略

  摘要：

  通过将磷酸化和缩合步骤结合在顺序反应系列中，已实现了60-85％分离产率的双脱氧核糖核苷酸嵌段的快速合成，这也允许回收未反应的核苷酸。

  DOI：

  10.1016/s0040-4039(01)81907-9

文献信息

• Transition States and Control of Substrate Preference in the Promiscuous Phosphatase PP1
  作者：Yuan Chu、Nicholas H. Williams、Alvan C. Hengge

  DOI：10.1021/acs.biochem.7b00441

  日期：2017.8.1

  monoester substrate, PP1γ catalyzes the hydrolysis of aryl methylphosphonates, fluorophosphate esters, phosphorothioate esters, and phosphodiesters, with second-order rate accelerations that fall within the narrow range of 1011–1013. In contrast to the different transition states in the uncatalyzed hydrolysis reactions of these substrates, PP1γ catalyzes their hydrolysis through similar transition states

  催化混杂酶是生物化学的一个有吸引力的前沿领域，因为酶混杂不仅可以通过基因复制机制合理地解释酶的进化，而且可以通过模仿这种进化过程来提供改变蛋白质催化功能的有效途径。PP1γ是一种有效的混杂磷酸酶，可水解基于单阴离子和双阴离子磷酸酯的底物。除了其天然的磷酸单酯底物外，PP1γ还催化芳基甲基膦酸酯，氟代磷酸酯，硫代磷酸酯和磷酸二酯的水解，其二级速率加速范围在10 11 –10 13的狭窄范围内。。与这些底物的未催化水解反应中的不同过渡态相反，PP1γ通过相似的过渡态催化其水解。PP1γ不会催化硫酸酯的水解，这是出乎意料的。PP1γ活性位点可耐受结合的配体的几何形状变化，即使在初始酶-底物复合物和过渡态中，其空间要求可能会干扰转移基团定位的底物也可有效催化状态。精氨酸221向赖氨酸的保守突变导致突变体，其是对单阴离子底物更有效的催化剂。
• [EN] CYCLIC PHOSPHATE SUBSTITUTED NUCLEOSIDE DERIVATIVES FOR THE TREATMENT OF LIVER DISEASES<br/>[FR] DÉRIVÉS DE NUCLÉOSIDES CYCLIQUES À SUBSTITUTION PHOSPHATE POUR LE TRAITEMENT DE MALADIES HÉPATIQUES
  申请人：IDENIX PHARMACEUTICALS LLC

  公开号：WO2018091542A1

  公开（公告）日：2018-05-24

  The present invention relates to Compounds of Formula (I) or Formula (II) or a pharmaceutically acceptable salt, solvate or enantiomer thereof, wherein A, B, R1, R2, R3, R4, Q and V are as defined herein. The present invention also relates to pharmaceutical compositions comprising a Compound of Formula (I) or Formula (II) and to their use in therapy.

  本发明涉及式（I）或式（II）的化合物或其药用可接受的盐、溶剂化合物或对映体，其中A、B、R1、R2、R3、R4、Q和V如本文所定义。本发明还涉及包括式（I）或式（II）的化合物的药物组合物，并其在治疗中的应用。
• NUCLEOSIDE ANALOGUES WHOSE SUGAR MOIETIES ARE BOUND IN S-FORM AND OLIGONUCLEOTIDE DERIVATIVES COMPRISING NUCLEOTIDE ANALOGUES THEREOF
  申请人：Imanishi, Takeshi

  公开号：EP1486504A1

  公开（公告）日：2004-12-15

  Compounds of the following general formula (1) and salts thereof: where A represents an alkylene group having 1 to 2 carbon atoms, etc.; B represents an aromatic heterocyclic group which may have a substituent, etc.; R1 and R2 each represent a hydrogen atom, a protective group for a hydroxyl group for synthesis of nucleic acid, a phosphate group, or -P(R4)R5 [where R4 and R5 are the same or different, and each represent a hydroxyl group, a hydroxyl group protected with a protective group for synthesis of nucleic acid, a mercapto group, a mercapto group protected with a protective group for synthesis of nucleic acid, etc.]; and R3 represents a hydrogen atom, a halogen atom, a hydroxyl group, a hydroxyl group protected with a protective group for synthesis of nucleic acid, etc. These compounds are useful for producing oligonucleotide analogues useful for the antisense method, antigene method, etc., and for producing their intermediates.

  以下通用式（1）及其盐的化合物：其中A代表具有1至2个碳原子的烷基基团等；B代表可能具有取代基的芳香杂环基团等；R1和R2分别代表氢原子，用于核酸合成的羟基保护基，磷酸基，或-P（R4）R5 [其中R4和R5相同或不同，每个代表羟基，用于核酸合成的羟基保护基，巯基，用于核酸合成的巯基保护基等]；R3代表氢原子，卤素原子，羟基，用于核酸合成的羟基保护基等。这些化合物可用于生产用于反义方法、抗基因方法等的寡核苷酸类似物，以及生产它们的中间体。
• Studies on deoxyribonucleic acids and related compounds. II. Synthesis of a decanucleotide containing a restriction enzyme (PstI) recognition site.
  作者：EIKO OHTSUKA、TEIICHI ONO、MORIO IKEHARA

  DOI：10.1248/cpb.29.3274

  日期：——

  A decanucleotide dC-C-C-T-C-G-A-G-G-G was synthesized by phosphotriester block condensation. Three protected blocks, dCCCTp, dCGAp and dGGG were prepared using N-acyl, 5'-O-monomethoxytrityldeoxynucleosides as the starting materials. The protected dGGG which served as the 3'-terminal block was synthesized by condensation of 3'-O-benzoyl-N-isobutyryldeoxyguanosine (5'-hydroxy component) with 5'-O-monomethoxytrityl-N-isobutyryldeoxyguanosine 3'-O-p-chlorophenyl phosphate (3'-O-phosphodie ster component) using mesitylenesulfonyl triazolide as the condensing reagent followed by removal of the 5'-monomethoxytrityl group for repeated condensation. The other two blocks were prepared by using the 3'-O-p-chlorophenyl phosphoranilidate of N, 5'-protected deoxynucleosides as the 3'-end unit (5'-hydroxy component). The phosphoranilidate of the fully protected trimers was removed by treatment with isoamyl nitrite for the condensation with the 5'-hydroxyl group of the growing chain. Fully protected nucleotides were isolated by chromatography on silica gel and the deblocked product was purified by ionexchange chromatography on DEAE-cellulose. The decanucleotide was characterized by mobility shift analysis and complete enzymatic digestions after labelling the 5'-end with [γ-32P] ATP using polynucleotide kinase.

  通过磷酸酯块缩合合成了十核苷酸 dC-C-C-T-C-G-A-G-G-G。以 N-酰基、5'-O-单甲氧基三苯甲基脱氧核苷酸为起始原料，制备了三个受保护的嵌段：dCCCTp、dCGAp 和 dGGG。作为 3'- 末端嵌段的受保护 dGGG 是通过 3'-O- 苯甲酰基-N-异丁酰基脱氧鸟苷（5'-羟基成分）与 5'-O- 单甲氧基三苯甲基-N-异丁酰基脱氧鸟苷 3'- O- 对氯苯基磷酸酯（5'-羟基成分）缩合合成的。O-对氯苯基磷酸酯（3'-O-磷酸酯成分），使用甲磺酰三唑烷作为缩合试剂，然后去除 5'-monomethoxytrityl 基团进行重复缩合。另外两个区块是以 N，5'-受保护的脱氧核苷的 3'-O-对氯苯基膦酰苯胺为 3'-末端单元（5'-羟基成分）制备的。用亚硝酸异戊酯处理完全保护的三聚体，使其与生长链的 5'-羟基缩合，从而除去完全保护的三聚体的磷酰苯胺。通过硅胶色谱法分离出完全保护的核苷酸，并通过 DEAE-纤维素离子交换色谱法纯化脱锁产物。在使用多核苷酸激酶用[γ-32P] ATP 标记 5'-end 后，十核苷酸的特征通过迁移分析和完全酶解来确定。
• Butyrylcholinesterase Inhibitors
  申请人：JAL Therapeutics, LLC

  公开号：US20160206635A1

  公开（公告）日：2016-07-21

  Butyrylcholinesterase inhibitors, their formulation, and their use primarily in the treatment of neurodegenerative diseases. These inhibitors generally are phosphates, phosphonates, phosphinates, and phosphoramidates. These inhibitors can be incorporated in pharmaceutical compositions and administered to a patient in therapeutically effective amounts to treat neurodegenerative diseases.

  丁酰胆碱酯酶抑制剂，它们的配方，以及它们主要用于治疗神经退行性疾病。这些抑制剂通常是磷酸酯、膦酸酯、膦酸酯和磷酰胺酯。这些抑制剂可以被纳入药物组成，并以治疗有效量的方式给患者使用，以治疗神经退行性疾病。